Annals of Thoracic and Cardiovascular Surgery
Online ISSN : 2186-1005
Print ISSN : 1341-1098
ISSN-L : 1341-1098
18 巻, 6 号
選択された号の論文の19件中1~19を表示しています
Editorial
Review Article
  • Koji Kono, Kousaku Mimura, Hideki Fujii, Asim Shabbir, Wei-Peng Yong, ...
    2012 年 18 巻 6 号 p. 506-513
    発行日: 2012年
    公開日: 2012/12/20
    [早期公開] 公開日: 2012/11/17
    ジャーナル フリー
    Despite improvements in surgical techniques and perioperative management and surgery combined with chemotherapy and/or radiotherapy, the prognosis of esophageal squamous cell carcinoma (SCC) at an advanced stage remains poor. Therefore, for esophageal SCC patients, novel therapies such as small molecule inhibitors of tyrosine kinases (TKIs) and humanized monoclonal antibodies (mAbs) are very much needed.Esophageal SCC shows a relatively high incidence of EGFR (33%) and/or HER2(31%) overexpression. Two categories of anti-HER-family-targeting therapies have been in clinical development: small-molecule, HER-family-related TKIs such as Gefitinib,Erlotinib and Lapatinib, and humanized mAbs against the HER family represented by Cetuximab and Trastuzumab. Although there have been very few clinical trials of antiHER-family targeting drugs in esophageal SCC, some in vitro data suggested that the combination of Cetuximab and Trastuzumab could induce synergistic antiproliferative effects and additional antibody-dependent cellular cytotoxicity (ADCC) activities against esophageal SCC cells. A better understanding of the detailed mechanisms involved in EGFR and/or HER2 may help identify new therapeutic targets in esophageal SCC.
Original Articles
  • Chitaru Kurihara, Takashi Nishimura, Kazuhito Imanaka, Shunei Kyo
    2012 年 18 巻 6 号 p. 514-518
    発行日: 2012/05/25
    公開日: 2012/12/20
    [早期公開] 公開日: 2012/05/15
    ジャーナル フリー
    Purpose: Ventricular assist devices have been used for the treatment of severe heart failure. Recently, many types of blood pumps have been developed to reduce major adverse events. EVAHEART® (Sun Medical Technology Research Corporation, Nagano, Japan) is an implantable centrifugal blood pump. In laboratory animal studies, the pump flow of EVAHEART® increases spontaneously during exercise with no changes in pump control parameters. However, this has not been confirmed clinically. The aim of this study was to analyze EVAHEART® performance during exercise.
    Patients and methods: Four male patients were implanted with an EVAHEART®. We evaluated the performance of the EVAHEART® during exercise. Fixed pump speeds were maintained during each test. Measurements during exercise were peak load, peak oxygen consumption (peak VO2), pre exercise pump flow, and peak velocity.
    Results: Pump flow significantly increased from 4.1 ± 0.5 liters per minute (L/min) to 7.2 ± 1.8 L/min during exercise. VO2 increased from 4.0 ± 0.7 milliliters per kilogram per minute (ml/kg/min) to 14.7 ± 3.3 ml/kg/min.
    Conclusion: These results indicate that EVAHEART® may support severe heart failure patients not only under static but also under dynamic conditions. Pump flow spontaneously increased during exercise at a constant pump speed.
  • Tetsuya Ueno, Ryuzo Sakata, Hiroyuki Yamamoto, Yosuke Hisashi, Koji Ta ...
    2012 年 18 巻 6 号 p. 519-523
    発行日: 2012/05/25
    公開日: 2012/12/20
    [早期公開] 公開日: 2012/06/15
    ジャーナル フリー
    Purpose: We investigated whether mitral annuloplasty (MAP) should be performed for mild ischemic mitral regurgitation (IMR).
    Methods: We selected 57 patients with preoperatively mild IMR. Twenty-eight patients who previously had moderate MR or more, underwent MAP (group 1) while 29 patients with persistent mild MR, did not (group 2). We reviewed MR changes and outcomes of these patients. We also investigated other IMR patients with preoperatively moderate or more MR as reference data (group 3).
    Results: In group 1, MR was none or trace in 25 patients immediately after operation, however, eleven out of these patients (44%) showed postoperative MR up-grade. The trends of MR changes in group 1 were similar to those of patients in group 3. In group 2, MR was graded mild in 79% of patients in mid-term postoperative stage although 28% of patients were up-graded or down-graded during postoperative follow-up.
    Conclusion: MAP is not necessary for patients with persistently mild IMR. Patients with preoperatively mild IMR with episodes of MR exacerbation had better be treated similarly as those with moderate or more IMR and undergo MAP.
  • Anna Grumann, Leonel Baretto, Anthony Dugard, Pierre Morera, Elisabeth ...
    2012 年 18 巻 6 号 p. 524-529
    発行日: 2012/06/25
    公開日: 2012/12/20
    [早期公開] 公開日: 2012/06/29
    ジャーナル フリー
    Purpose: To describe the clinical presentation and echocardiographic findings associated with localized tamponade after open-heart surgery.
    Methods: Retrospective analysis of a case series with a surgically proven diagnosis.
    Results: Among 23 patients with surgically proven localized cardiac tamponade after elective open-heart surgery, 5 patients (22%) died in the ICU from multiorgan failure. At the time of diagnosis (median delay: 2 days; range: 0–8 days), shock was present in 19 patients, 8 of them being hypotensive. Transthoracic echocardiography (TTE) depicted the localized cardiac tamponade in 3 of 4 examined patients, whereas transesophageal echocardiography (TEE) was always conclusive. The right atrium was primarily involved, solely (n = 11) or with the right ventricle (n = 5), whereas the left cardiac cavities were less frequently compressed (left atrium: n = 6, left ventricle: n = 1). The free wall curvature of the involved cardiac chamber was consistently inverted, and blood flow turbulences were depicted in 12 patients. Surgical removal of the compressive hematoma improved the clinical status of 18 patients (78%) who were discharged from the hospital.
    Conclusion: Since localized tamponade complicating open-heart surgery has various, non-specific clinical presentations and TTE is not diagnostic, indications of TEE must be liberal in this setting to prompt diagnosis and surgical reoperation.
  • Yasushi Shintani, Yasunobu Funakoshi, Masayoshi Inoue, Yukiyasu Takeuc ...
    2012 年 18 巻 6 号 p. 530-535
    発行日: 2012/05/25
    公開日: 2012/12/20
    [早期公開] 公開日: 2012/06/15
    ジャーナル フリー
    Objectives: The benefits of preoperative chemoradiotherapy for advanced nonsmall cell lung cancer (NSCLC) remain controversial. To evaluate prognostic indicators of clinical N2 NSCLC patients treated with concurrent chemotherapy followed by pulmonary resection, we performed a retrospective study.
    Methods: We retrospectively investigated 52 patients with pathologically proven N2 NSCLC who underwent concurrent chemoradiotherapy before pulmonary resection. Each received 2 cycles of cisplatin-vinca alkaloid-based chemotherapy every 4 weeks. Radiotherapy, directed at the tumor and mediastinal nodes, was started on day 2 at a median dose of 44 Gy. A thoracotomy was performed 6 to 8 weeks after completion of chemoradiotherapy.
    Results: The overall 5-year survival rate for the 52 patients was 38%. Complete pathological response by the tumor was found in 11 (21%). Down-staging of nodal stage occurred in 29 patients, (56%) and overall survival was better in those with lower pathological N status. The 5-year survival rate was 58% for pathological N0-N1 disease and 0% for N2 disease. While the response to induction therapy by the primary tumor was correlated with postoperative nodal stage, multivariate analysis revealed postoperative nodal stage as an independent prognostic factor.
    Conclusion: Pathological status of mediastinal lymph nodes in response to preoperative concurrent chemoradiotherapy determined prognosis in our patients.
Case Reports
Letter to the Editor
feedback
Top